TP53 and ovarian serous adenocarcinoma: In contrast, a recent study using a subset of the gene expression data from TCGA set for high grade serous ovarian cancers, has provided some evidence that patients with gain-of function p53 mutant proteins are characterized by a greater likelihood of platinum treatment resistance and distance metastasis (Kang et al., 2013).